← Leaderboards
Bhaskar Chandra Das
Albert Einstein College Of Medicine
$3,457,971
Attributed
$7,825,753
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,825,753 · 6
By mechanism
R01$6,225,661 · 3
R21$1,600,092 · 3
Top collaborators
- Daniela Annenelie Bota9 shared
- Louis M. Weiss6 shared
- Frankie G Almaguel4 shared
- Carlos A Casiano4 shared
- Anne Muesch3 shared
- Mariko Saito3 shared
- John C He2 shared
- Kyung W Lee2 shared
Others in their field
Top investigators on “Novel Therapeutics”
- David Heimbrook · Leidos Biomedical Research, Inc.$355,066,875
- Judith S. Currier · University Of California Los Angeles$321,442,024
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Daniel R Kuritzkes · Brigham And Women'S Hospital$246,024,897
- Sharon A Nachman · Johns Hopkins University$212,395,175
Research focus
Novel TherapeuticsResistanceLeadIn VivoToxic EffectCellsIn VitroStructure-Activity RelationshipLibrariesPathway InteractionsProteinsDrug TargetingInterestBindingResponseGenesGrowthBiologicalIn Vivo ModelSmall MoleculeMolecularAnimal ModelTherapy ResistantTumor
Grant awards (27)
KLF2 is a novel endoprotective target for DKD$721,246
R01 · FY2025 · DK
KLF2 is a novel endoprotective target for DKD$740,566
R01 · FY2024 · DK
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$399,338
R01 · FY2024 · NS
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$212,181
R21 · FY2024 · CA
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$74,406
R21 · FY2024 · CA
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$9,145
R01 · FY2024 · NS
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2023 · NS
Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities$186,539
R21 · FY2023 · CA
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$78,339
R01 · FY2023 · NS
Administrative Diversity Supplement to: "Role and Theranostics Potential of Enolase in Prostate Cancer Health Disparities"$63,587
R21 · FY2023 · CA
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2022 · NS
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$401,250
R01 · FY2022 · AI · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$78,339
R01 · FY2022 · NS
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2021 · NS
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$401,250
R01 · FY2021 · AI · contact PI
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$390,001
R01 · FY2021 · AI · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$71,810
R01 · FY2021 · NS
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$425,938
R01 · FY2020 · NS
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$414,750
R01 · FY2020 · AI · contact PI
Receptor Specific Retinoids Probes to Study the Brain Damage Caused by Developmental Alcohol Exposure$222,584
R21 · FY2020 · AA · contact PI
Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol Exposure$194,293
R21 · FY2020 · AA · contact PI
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$420,625
R01 · FY2019 · AI · contact PI
Receptor Specific Retinoids Probes to Study the Brain Damage Caused by Developmental Alcohol Exposure$258,251
R21 · FY2019 · AA · contact PI
Development of Novel MetAP2 inhibitors as potential therapeutics for Microsporidiosis$438,000
R01 · FY2018 · AI · contact PI
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)$149,625
R21 · FY2012 · AA · contact PI
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)$212,132
R21 · FY2011 · AA · contact PI
Development of Small Molecule Mimetics of hepatocyte Growth Factor (HGF)$26,494
R21 · FY2011 · AA · contact PI